Monday, October 24, 2016

Ortho Tri-Cyclen


See also: Generic Ortho Tri-Cyclen Lo


Ortho Tri-Cyclen is a brand name of ethinyl estradiol/norgestimate, approved by the FDA in the following formulation(s):


ORTHO TRI-CYCLEN (ethinyl estradiol; norgestimate - tablet; oral-28)



  • Manufacturer: JANSSEN PHARMS

    Approval date: July 3, 1992

    Strength(s): 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG [RLD][AB]

Has a generic version of Ortho Tri-Cyclen been approved?


Yes. The following products are equivalent to Ortho Tri-Cyclen:


NORGESTIMATE AND ETHINYL ESTRADIOL (ethinyl estradiol; norgestimate tablet; oral-28)



  • Manufacturer: WATSON LABS

    Approval date: August 17, 2006

    Strength(s): 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG [AB]

TRI-PREVIFEM (ethinyl estradiol; norgestimate tablet; oral-28)



  • Manufacturer: VINTAGE

    Approval date: March 26, 2004

    Strength(s): 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG [AB]

TRI-SPRINTEC (ethinyl estradiol; norgestimate tablet; oral-28)



  • Manufacturer: BARR

    Approval date: December 29, 2003

    Strength(s): 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ortho Tri-Cyclen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Ortho Tri-Cyclen.

See also...

  • Ortho Tri-Cyclen Consumer Information (Drugs.com)
  • Ortho Tri-Cyclen Consumer Information (Wolters Kluwer)
  • Ortho Tri-Cyclen Consumer Information (Cerner Multum)
  • Norgestimate and Ethinyl Estradiol Consumer Information (Wolters Kluwer)
  • Ortho-Tri-Cyclen Consumer Information (Wolters Kluwer)
  • Ethinyl estradiol and norgestimate Consumer Information (Cerner Multum)

No comments:

Post a Comment